Covered recipient · General Payments record
STEVEN L MCCUNE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$111,917.66
120 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,115.00 | 28 |
| Travel and Lodging | $10,323.87 | 35 |
| Consulting Fee | $7,397.50 | 8 |
| Food and Beverage | $2,081.29 | 49 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $107,900.49 | 87 |
| AstraZeneca Pharmaceuticals LP | $2,622.89 | 5 |
| Genentech USA, Inc. | $561.21 | 2 |
| Celgene Corporation | $453.84 | 8 |
| Pharmacyclics LLC, an AbbVie Company | $106.94 | 4 |
| Amgen Inc. | $67.89 | 3 |
| Regeneron Healthcare Solutions, Inc. | $62.12 | 2 |
| PFIZER INC. | $24.83 | 2 |
| Novartis Pharmaceuticals Corporation | $23.82 | 1 |
| Merck Sharp & Dohme LLC | $17.47 | 1 |
| Seagen Inc. | $16.45 | 1 |
| Astellas Pharma US Inc | $16.00 | 1 |
| Mylan Institutional Inc. | $15.21 | 1 |
| Daiichi Sankyo Inc. | $14.28 | 1 |
| Kite Pharma, Inc. | $14.22 | 1 |
Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEVEN L MCCUNE
NPI 1043215452 · CMS profile ID 137445
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MARIETTA, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- STEVEN L MCCUNE, NPI 1043215452, CMS profile ID 137445, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043215452?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
120 matching records · $111,917.66 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–120 of 120.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,400.00 | 04/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519765 | CMS |
| E.R. Squibb & Sons, L.L.C. | $109.44 | 04/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519763 | CMS |
| E.R. Squibb & Sons, L.L.C. | $359.44 | 04/20/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519755 | CMS |
| E.R. Squibb & Sons, L.L.C. | $120.54 | 04/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519769 | CMS |
| Genentech USA, Inc. | $550.00 | 04/20/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950666555 | CMS |
| E.R. Squibb & Sons, L.L.C. | $269.10 | 04/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519741 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,780.00 | 04/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519743 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,665.00 | 04/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519887 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.75 | 04/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519733 | CMS |
| E.R. Squibb & Sons, L.L.C. | $129.18 | 04/11/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519775 | CMS |
| E.R. Squibb & Sons, L.L.C. | $539.17 | 04/06/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519865 | CMS |
| E.R. Squibb & Sons, L.L.C. | $122.92 | 04/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519875 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.00 | 04/06/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519877 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,400.00 | 04/05/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519725 | CMS |
| Merck Sharp & Dohme LLC | $17.47 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944141159 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,235.00 | 03/01/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519713 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,400.00 | 02/22/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519711 | CMS |
| Amgen Inc. | $21.61 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939944889 | CMS |
| Amgen Inc. | $20.47 | 02/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939944891 | CMS |
| Celgene Corporation | $23.45 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932519709 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $469.66 | 2 |
| PY2025 | Principal investigator | $2,388,421.94 | 127 |
| PY2024 | Recipient | $13,979.36 | 6 |
| PY2024 | Principal investigator | $3,388,675.71 | 152 |
| PY2023 | Recipient | $5,123.43 | 4 |
| PY2023 | Principal investigator | $3,199,315.64 | 295 |
| PY2022 | Recipient | $2,540.00 | 4 |
| PY2022 | Principal investigator | $2,950,719.39 | 225 |
| PY2021 | Recipient | $4,760.00 | 8 |
| PY2021 | Principal investigator | $2,560,219.47 | 224 |
| PY2020 | Recipient | $1,694.00 | 1 |
| PY2020 | Principal investigator | $2,434,456.25 | 620 |
| PY2019 | Principal investigator | $2,131,035.78 | 317 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
129 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 2 | Merck Sharp & Dohme LLC | $8,792.20 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations | No dispute reported | 06/30/2026 | 1232923262 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,270.37 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cisplatin as First-Line Therapy in Participants with Advanced and,or Unresectable Biliary Tract Carcinoma | No dispute reported | 06/30/2026 | 1232927457 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $44,449.53 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928694 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,672.19 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 | No dispute reported | 06/30/2026 | 1232928888 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,622.54 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931486 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $56,019.54 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935159 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,300.50 | 12/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232939897 |
| Principal investigator 1 | SEAGEN INC. | $1,757.00 | 12/09/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228726500 |
| Recipient | Novartis Pharmaceuticals Corporation | $332.54 | 12/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291276 |
| Principal investigator 1 | BeOne Medicines Ltd. | $94,320.00 | 12/01/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330357 |
| Principal investigator 1 | SEAGEN INC. | $4,582.00 | 11/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228726965 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $28,715.00 | 11/05/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935157 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 10/24/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336785 |
| Principal investigator 1 | BeOne Medicines Ltd. | $110,040.00 | 10/21/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330303 |
| Principal investigator 1 | SEAGEN INC. | $1,500.00 | 10/07/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228723544 |
| Principal investigator 1 | SEAGEN INC. | $4,700.00 | 10/07/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228726520 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $121.59 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants with EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer NSCLC Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors | No dispute reported | 06/30/2026 | 1232922880 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $99,630.72 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater Than or Equal To 50 | No dispute reported | 06/30/2026 | 1232923238 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $33,210.24 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1232924146 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $162.12 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastroesophageal Junction Adenoca | No dispute reported | 06/30/2026 | 1232924238 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $70,974.08 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928696 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $81.06 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers | No dispute reported | 06/30/2026 | 1232933350 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $132,615.60 | 08/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935161 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $8,001.00 | 08/20/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530896 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 08/05/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336937 |
| Recipient | Novartis Pharmaceuticals Corporation | $137.12 | 08/05/2025 | Covered Recipient Physician | CABL001AUS08 | No dispute reported | 06/30/2026 | 1190292819 |
| Principal investigator 1 | Genentech, Inc. | $2,550.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tecentriq Oncology Extension Study | No dispute reported | 06/30/2026 | 1211631360 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143313 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143317 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143326 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143330 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144926 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144931 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144940 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144944 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $150.00 | 07/29/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144948 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 07/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143309 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 07/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 07/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144922 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,550.00 | 07/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192144935 |
| Principal investigator 1 | BeOne Medicines Ltd. | $78,600.00 | 07/07/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330317 |
| Principal investigator 1 | Genentech, Inc. | $4,738.00 | 07/02/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211631403 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,125.00 | 07/02/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928656 |
| Principal investigator 1 | SEAGEN INC. | $650.00 | 07/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228742601 |
| Principal investigator 1 | SEAGEN INC. | $500.00 | 07/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228743577 |
| Principal investigator 1 | Exelixis Inc. | $22,430.00 | 06/26/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382828 |
| Principal investigator 1 | Exelixis Inc. | $878.00 | 06/26/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382832 |
| Principal investigator 1 | Genentech, Inc. | $23,715.00 | 06/25/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | INAVO123 | No dispute reported | 06/30/2026 | 1211631396 |
| Principal investigator 1 | SEAGEN INC. | $1,600.00 | 06/25/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1228791911 |
| Principal investigator 1 | Genentech, Inc. | $5,648.00 | 06/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631368 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 06/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192134182 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 06/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192134189 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,800.00 | 06/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143302 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,800.00 | 06/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192143305 |
| Principal investigator 1 | Exelixis Inc. | $3,118.85 | 06/20/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382830 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,671.00 | 06/17/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190326090 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,851.00 | 06/16/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190331467 |
| Principal investigator 1 | SEAGEN INC. | $1,750.00 | 06/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1228789913 |
| Principal investigator 1 | SEAGEN INC. | $9,350.00 | 06/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTI COHORT OPEN LABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48 ADC IN SUBJECTS WITH HER2 EXPRESSING LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA | No dispute reported | 06/30/2026 | 1228790431 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,902.00 | 05/30/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190326088 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 05/27/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336774 |
| Principal investigator 1 | Genentech, Inc. | $100.00 | 05/27/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211631481 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 05/27/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211631487 |
| Principal investigator 1 | Genentech, Inc. | $1,264.00 | 05/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631364 |
| Principal investigator 1 | Exelixis Inc. | $2,704.00 | 05/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382818 |
| Principal investigator 1 | Exelixis Inc. | $18,290.00 | 05/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382822 |
| Principal investigator 1 | Exelixis Inc. | $9,941.00 | 05/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382824 |
| Principal investigator 1 | Exelixis Inc. | $676.00 | 05/19/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382826 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,408.08 | 05/14/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC | No dispute reported | 06/30/2026 | 1185544159 |
| Principal investigator 1 | AstraZeneca UK Limited | $41,494.00 | 05/14/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185544161 |
| Principal investigator 1 | BeiGene, Ltd. | $78,600.00 | 05/08/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322116 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 05/01/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323574 |
| Principal investigator 1 | Genentech, Inc. | $518.40 | 05/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211631491 |
| Principal investigator 1 | Genentech, Inc. | $5,200.00 | 04/28/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC | No dispute reported | 06/30/2026 | 1211631495 |
| Principal investigator 1 | Genentech, Inc. | $4,550.00 | 04/28/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | GDC 9545 vs single agent endocrine therapy of physician s choice in HR 2L 3L mBC | No dispute reported | 06/30/2026 | 1211631498 |
| Principal investigator 1 | Genentech, Inc. | $3,705.00 | 04/23/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211631433 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,412.00 | 04/22/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190326092 |
| Principal investigator 1 | Exelixis Inc. | $4,647.40 | 04/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382820 |
| Principal investigator 1 | Genentech, Inc. | $8,570.00 | 04/09/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631375 |
| Principal investigator 1 | Genentech, Inc. | $676.00 | 04/08/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211631430 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,700.00 | 04/07/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190338520 |
| Principal investigator 1 | Genentech, Inc. | $8,743.00 | 04/02/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211631372 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,950.50 | 03/31/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190327213 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $5,165.00 | 03/25/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190326086 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,057.00 | 03/24/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190338515 |
| Principal investigator 1 | Genentech, Inc. | $348.00 | 03/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631443 |
| Principal investigator 1 | Genentech, Inc. | $101.00 | 03/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631447 |
| Principal investigator 1 | Genentech, Inc. | $203.00 | 03/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631452 |
| Principal investigator 1 | Genentech, Inc. | $744.00 | 03/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631456 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 03/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631460 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,550.00 | 03/24/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 | No dispute reported | 06/30/2026 | 1232928886 |
| Principal investigator 1 | Exelixis Inc. | $2,530.80 | 03/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382810 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,086.00 | 03/19/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232934938 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,500.00 | 03/17/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment | No dispute reported | 06/30/2026 | 1232937008 |
| Principal investigator 1 | Genentech, Inc. | $8,386.90 | 03/14/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tecentriq Oncology Extension Study | No dispute reported | 06/30/2026 | 1211631356 |
| Principal investigator 1 | ABBVIE INC. | $20,190.00 | 03/07/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202461953 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,869.00 | 03/03/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321536 |
| Principal investigator 1 | SEAGEN INC. | $11,775.00 | 02/27/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228773068 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,600.00 | 02/26/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 | No dispute reported | 06/30/2026 | 1185544165 |
| Principal investigator 1 | Eli Lilly and Company | $76.65 | 02/25/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187872365 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 02/24/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325306 |
| Principal investigator 1 | Genentech, Inc. | $1,191.00 | 02/20/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer | No dispute reported | 06/30/2026 | 1211631400 |
| Principal investigator 1 | Exelixis Inc. | $7,835.60 | 02/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382808 |
| Principal investigator 1 | Genentech, Inc. | $4,550.00 | 02/10/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211631412 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 02/05/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323600 |
| Principal investigator 1 | Genentech, Inc. | $1,040.00 | 02/05/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631465 |
| Principal investigator 1 | BeiGene, Ltd. | $125,760.00 | 01/30/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322120 |
| Principal investigator 1 | Genentech, Inc. | $2,746.00 | 01/28/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211631420 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,902.00 | 01/27/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers - Marietta | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325212 |
| Principal investigator 2 | E.R. Squibb & Sons, L.L.C. | $299.32 | 01/27/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235995209 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,550.00 | 01/27/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Center, P.c. | A Phase II Open Label Randomized Study of MORAb-202 (farletuzumab ecteribulin, an antibody drug conjugate) in participants with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma after progression on prior therapies. | No dispute reported | 06/30/2026 | 1235995221 |
| Principal investigator 1 | Exelixis Inc. | $6,105.65 | 01/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382816 |
| Principal investigator 1 | Genentech, Inc. | $5,604.00 | 01/24/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211631407 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $31,480.00 | 01/24/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers, PC | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530892 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,200.00 | 01/22/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Center, P.c. | A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers | No dispute reported | 06/30/2026 | 1235995219 |
| Principal investigator 1 | Genentech, Inc. | $202.00 | 01/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631469 |
| Principal investigator 1 | Genentech, Inc. | $1,525.00 | 01/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631474 |
| Principal investigator 1 | Genentech, Inc. | $203.00 | 01/21/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211631477 |
| Principal investigator 1 | Genentech, Inc. | $3,702.60 | 01/17/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Atezolizumab Carboplatin Etoposide Tiragolumab or Placebo in 1L ES SCLC | No dispute reported | 06/30/2026 | 1211631425 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 01/14/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325328 |
| Principal investigator 1 | AstraZeneca UK Limited | $16,628.65 | 01/13/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1185544163 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $500.00 | 01/13/2025 | Non-covered Recipient Entity Northwest Georgia Oncology Centers PC | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | No dispute reported | 06/30/2026 | 1232931484 |
| Principal investigator 1 | Exelixis Inc. | $133.20 | 01/09/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382812 |
| Principal investigator 1 | Genentech, Inc. | $1,076.00 | 01/08/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC | No dispute reported | 06/30/2026 | 1211631416 |
| Principal investigator 1 | Genentech, Inc. | $4,200.00 | 01/08/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211631427 |
| Principal investigator 1 | Genentech, Inc. | $9,162.00 | 01/07/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | Tecentriq Oncology Extension Study | No dispute reported | 06/30/2026 | 1211631352 |
| Principal investigator 1 | Exelixis Inc. | $592.00 | 01/03/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS PC | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222382814 |
| Principal investigator 1 | BeiGene, Ltd. | $15,120.00 | 01/02/2025 | Non-covered Recipient Entity NW GEORGIA ONC Ctrs | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323658 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $711,103.06 | 01/01/2025 | Non-covered Recipient Entity NORTHWEST GEORGIA ONCOLOGY CENTERS, PC | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190305015 |